相关实验视频

Updated: May 20, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

索福斯布维尔基基治疗后慢性肝炎C患者的长期肝脏和肝外结局 (LONGHEAD研究)

Chung-Feng Huang¹, Jeong Heo², Rong-Nan Chien³

¹Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung Medical University, 100 Tzyou Road, Kaohsiung, 807, Taiwan.

Infectious diseases and therapy

|April 9, 2025

概括

直接作用抗病毒药物 (DAA) 显著改善了型肝炎患者的长期健康结果,减少了肝纤维化和心血管事件. 在成功根除HCV后,生活质量得到维持.

科学领域:

肝病学肝病学是一种肝病学.
病毒学病毒学
临床医学临床医学

背景情况:

直接作用抗病毒药物 (DAA) 提供高度有效的C型肝炎病毒 (HCV) 治疗.
慢性型肝炎 (CHC) 患者在DAA治疗后的长期肝脏和肝外结局仍然不完全理解.

研究的目的:

评估使用DAA治疗的CHC患者的长期 (5年) 肝脏和肝外结局.
将DAA结果与基于干扰素的历史治疗队列进行比较.

主要方法:

在DAA治疗后获得持续病毒学反应的160名CHC患者的前性随访 (2013-2014年试验).
与480名接受干扰素治疗的患者的倾向评分匹配历史队列进行比较.
评估生活质量 (SF-36),肝纤维化 (电图) 和纤维化标志物 (FIB-4,M2BPGi,LOXL2).

主要成果:

肝细胞癌 (HCC) 的发病率在DAA和干扰素组之间相似 (每年0.6%);FIB-4是HCC的唯一独立预测因子.
与干扰素相比,DAA治疗显著减少了心脑血管事件 (每1000人年0.9对13.8).
在5年内观察到肝纤维化标志物 (M2BPGi,LOXL2) 和肝硬度的显著回归;生活质量普遍保持,身体/情绪角色限制略有下降.

结论:

用DAA消除HCV导致肝脏和非肝脏结局的持续改善.
治疗DAA促进持续性肝纤维化回归,并保持治疗后的生活质量.
在接受治疗的CHC患者中,FIB-4是HCC发展的关键预测因子.

关键词:

美国地方检察长:DAA 在HCV病毒感染的过程中,长期结果长期结果这是一个SVRSVR.

更多相关视频

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

相关概念视频

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...